M. Babaoglu Et Al. , "CYP2C9 genetic variants and losartan oxidation in a Turkish population," EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.60, no.5, pp.337-342, 2004
Babaoglu, M. Et Al. 2004. CYP2C9 genetic variants and losartan oxidation in a Turkish population. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.60, no.5 , 337-342.
Babaoglu, M., Yasar, U., Sandberg, M., Eliasson, E., Dahl, M., Kayaalp, S., ... Bozkurt, A.(2004). CYP2C9 genetic variants and losartan oxidation in a Turkish population. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.60, no.5, 337-342.
Babaoglu, MO Et Al. "CYP2C9 genetic variants and losartan oxidation in a Turkish population," EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.60, no.5, 337-342, 2004
Babaoglu, MO Et Al. "CYP2C9 genetic variants and losartan oxidation in a Turkish population." EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.60, no.5, pp.337-342, 2004
Babaoglu, M. Et Al. (2004) . "CYP2C9 genetic variants and losartan oxidation in a Turkish population." EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , vol.60, no.5, pp.337-342.
@article{article, author={MO Babaoglu Et Al. }, title={CYP2C9 genetic variants and losartan oxidation in a Turkish population}, journal={EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY}, year=2004, pages={337-342} }